Page 20 of 21

PA28.1-6 | Male Genital Tract — Case Study

CLINICAL SCENARIO

This assignment presents a real-world clinical scenario involving a 68-year-old man with lower urinary tract symptoms (LUTS) and a raised serum PSA. Your task is to work through the pathological basis of his presentation in a structured, evidence-based write-up that integrates clinical findings with gross morphology, histopathology, tumour markers, grading and staging, pathogenesis, and prognosis.

A detailed rubric guides the assessment. Your submission will be peer-reviewed by two classmates before receiving faculty feedback. Aim for analytical depth rather than factual enumeration — the goal is to demonstrate pathological reasoning, not memorisation.

Instructions

Read the clinical scenario carefully before beginning. Identify all clinically significant features.
Using the Scaffolding Sections below as your structural framework, write a continuous, well-argued case analysis. Do not answer in bullet lists within a section; use prose.
Cite specific histological features and macro-pathological changes where asked — vague generalisations will attract lower rubric scores.
For grading and staging, apply the Gleason grading system for prostatic adenocarcinoma and TNM staging where appropriate.
The pathogenesis section must connect molecular/cellular mechanisms to the clinical and morphological features observed — do not simply list risk factors.
Complete your write-up within the 600–900 word limit (excluding section headings).
After submission, you will be assigned two peers to review. Use the Peer Review Instructions section and the same rubric to assess their work within 72 hours.

CLINICAL SCENARIO

Mr. Ramesh Rao, a 68-year-old retired schoolteacher, presents to the urology outpatient department with a 10-month history of increasing difficulty initiating micturition, a weak and interrupted urinary stream, nocturia (3–4 times per night), and a sensation of incomplete bladder emptying. He denies haematuria or dysuria. His wife noticed that he appeared fatigued over the past two months. Past history is unremarkable apart from well-controlled Type 2 diabetes mellitus.

On digital rectal examination (DRE), the prostate is enlarged (estimated 55–60 g), firm, and nodular, with obliteration of the median sulcus. A hard, irregular nodule is palpated in the left posterior lobe.

Investigations:
- Total serum PSA: 18.4 ng/mL (normal < 4.0 ng/mL)
- Free PSA: 12% of total PSA
- TRUS-guided systematic biopsy: 12 cores obtained
- Biopsy report: 6 of 12 cores positive for adenocarcinoma; Gleason pattern 4 in dominant glands, Gleason pattern 3 in secondary glands; perineural invasion noted; 2 cores show benign prostatic hyperplasia
- PSMA PET-CT: localised disease; no pelvic lymph node or distant metastasis
- Serum creatinine: 1.3 mg/dL; MRI pelvis: tumour confined to the prostate (stage T2c)

Length: 600–900 words (excluding section headings and the clinical scenario text)

What to Submit

Section 1 — Clinical Summary and Differential Diagnosis

Summarise the key clinical features that inform a pathological differential diagnosis. Construct a prioritised differential for this presentation (at minimum: prostatic adenocarcinoma, benign prostatic hyperplasia, prostatitis, prostatic intraepithelial neoplasia as a precursor finding). Justify why prostatic adenocarcinoma is the most likely diagnosis and which features make BPH alone insufficient to explain the full picture. (~100–130 words)

Section 2 — Gross and Microscopic Pathological Features

Describe the expected gross appearance of the resected or biopsied prostate, including zone of origin, cut-surface colour and consistency, and any infiltrative margins. Then describe the defining histological features of prostatic adenocarcinoma at the Gleason pattern 3 and pattern 4 levels — gland architecture, nuclear features, nucleolar prominence, and perineural invasion. Contrast these with the concurrent BPH findings (glandular and stromal hyperplasia, corpora amylacea). (~150–200 words)

Section 3 — Tumour Markers and Investigations

Interpret the PSA findings in depth: explain why total PSA alone may be insufficient and how the free-to-total PSA ratio refines risk stratification. Describe the biological basis of PSA elevation in both BPH and carcinoma. Comment on the role of TRUS-guided biopsy core positivity and PSMA PET-CT in disease localisation. Mention any additional markers (e.g., PSMA, PCA3) that would be relevant in current practice. (~100–130 words)

Section 4 — Gleason Grading and TNM Staging

Assign and justify the Gleason score and Grade Group for this biopsy. Explain how Gleason pattern scoring (primary + secondary pattern) translates into a combined score and Grade Group (ISUP 2016 classification). Apply TNM staging using the MRI and PSMA data provided (T, N, M categories). State the clinical significance of perineural invasion as an adverse pathological feature. (~80–100 words)

Section 5 — Pathogenesis

Explain the molecular and cellular events underpinning the development of prostatic adenocarcinoma, beginning with prostatic intraepithelial neoplasia (PIN) as the precursor lesion. Discuss the role of androgen receptor signalling, TMPRSS2-ERG gene fusion, loss of PTEN, and the contribution of luminal epithelial cell transformation. Connect these mechanisms to the observed histological features (gland fusion, loss of basal cell layer, nucleolar enlargement). Avoid listing risk factors in isolation — integrate mechanism with morphology. (~120–150 words)

Section 6 — Prognosis and Management Implications

Based on the Gleason score, Grade Group, staging, and adverse histological features, summarise the prognostic category for this patient (NCCN or EAU risk classification is acceptable). Briefly outline how the pathological findings directly inform the choice between active surveillance, radical prostatectomy, radiotherapy, and androgen deprivation therapy. State the expected 10-year cancer-specific survival for this risk category. (~80–100 words)

Grading Rubric — Male Genital Tract Case Study Rubric

Criterion	Points	Full-marks descriptor
Differential Diagnosis and Clinical Reasoning — Assesses whether the student constructs a coherent, prioritised differential, correctly identifies the most likely diagnosis, and justifies it using specific clinical, DRE, and laboratory data rather than listing diagnoses in isolation.	6 pts	Full marks: Prioritised differential with at least 3 diagnoses; carcinoma correctly ranked first with explicit reasoning linking DRE nodule, PSA ratio, and biopsy; competing diagnoses distinguished on pathological grounds.
Gross and Microscopic Pathological Description — Assesses accuracy and specificity of morphological description for both prostatic adenocarcinoma (Gleason patterns 3 and 4) and the concurrent BPH component; tests whether the student can distinguish features at the histological level rather than providing textbook generalisations.	7 pts	Full marks: Accurate gross description (zone, consistency, infiltration); Gleason 3 and 4 architectures clearly distinguished (discrete glands vs. fused/cribriform); nuclear and nucleolar features described; perineural invasion noted; BPH features contrasted.
Tumour Markers and Investigative Interpretation — Assesses depth of understanding of PSA biology, the free-to-total PSA ratio, the role of TRUS-guided biopsy core positivity, and contextual knowledge of modern markers (PSMA, PCA3). Tests application of laboratory data to clinical decision-making rather than rote recall.	5 pts	Full marks: PSA biology explained in carcinoma vs. BPH; free-to-total ratio interpreted correctly (low ratio = higher malignancy risk); core positivity significance discussed; at least one additional contemporary marker mentioned with rationale.
Gleason Grading and TNM Staging — Assesses correct application of Gleason scoring (primary + secondary pattern → combined score and ISUP Grade Group), accurate TNM assignment using the data provided, and appreciation of perineural invasion as an adverse feature with prognostic weight.	6 pts	Full marks: Gleason score 4+3=7 stated and derived correctly; Grade Group 3 assigned with ISUP 2016 rationale; TNM stated as at least T2cN0M0; perineural invasion discussed as adverse feature affecting surgical margin and recurrence risk.
Pathogenesis — Assesses the student's ability to construct a mechanistic, integrated account of prostatic carcinogenesis — from PIN as precursor through androgen receptor signalling, key molecular events (TMPRSS2-ERG, PTEN loss), and transformation of luminal epithelium — linking molecular events to observable morphological features rather than listing risk factors.	6 pts	Full marks: PIN introduced as precursor; androgen receptor role explained; at least two specific molecular events (TMPRSS2-ERG and/or PTEN) discussed with functional consequence; loss of basal cell layer and nucleolar changes linked to transformation; mechanisms connected to observed morphology.

PEER REVIEW

You have been assigned two submissions to review. For each submission:

Read the entire case analysis before scoring any criterion.
Apply the rubric above criterion by criterion. For each criterion, select the rating level that best matches the work — do not round up out of sympathy or down out of competition. Provide a 2–3 sentence written justification for every score you assign.
Write one 'Strength' comment (what the author did well, with specific reference to their text) and one 'Improvement' comment (what would most improve the analysis, with a concrete suggestion — not just 'needs more detail').
Be constructive and specific. Comments such as 'good job' or 'needs work' without evidence from the submission are not acceptable peer reviews and will receive zero marks for the review component.
Do not alter your scores after reading the author's reaction or the faculty grade — your honest independent assessment is the learning goal.
Your peer review quality will itself be graded by faculty on a 5-point scale (accuracy of rubric application and quality of written feedback).